Blockchain Registration Transaction Record

Co-Diagnostics Expands South Asian Reach to $13B Market via CoSara Venture

Co-Diagnostics expands CoSara joint venture across South Asia, targeting $13B market with PCR Pro® and SARAGENE® diagnostics platforms in Bangladesh, Pakistan, Nepal, Sri Lanka.

This expansion matters because it represents a strategic move to address critical healthcare gaps in South Asia, home to over 1.8 billion people across Bangladesh, Pakistan, Nepal, and Sri Lanka. The region faces significant challenges in diagnostic infrastructure, particularly for infectious diseases that require rapid, accurate testing. By introducing the CoSara PCR Pro® point-of-care platform and SARAGENE® product line, Co-Diagnostics could potentially improve healthcare outcomes through faster diagnosis and treatment initiation. For investors, this signals aggressive growth strategy in emerging markets with substantial unmet medical needs. For the global healthcare landscape, it demonstrates how molecular diagnostics companies are expanding access to advanced testing technologies in developing regions, potentially setting new standards for diagnostic capabilities across South Asia's healthcare systems.